INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

INDICATION & USAGE

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO, including protamine sulfate  a compound known to cause hypersensitivity reactions in some individuals  is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

    

 

 

The Facts About Japanese Encephalitis (JE)

Unpredictable. Dangerous.
Preventable.

A traveler to any of 24 countries in Asia can be infected with JE virus.1 Although rare, when viral infection results in JE disease, the consequences can be devastating.1

A traveler to any of 24 countries in Asia can be infected with JE virus.1 Although rare, when viral infection results in JE disease, the consequences can be devastating.1

What is JE?

JE is a mosquito-borne disease of the genus Flavivirus, which is related to mosquito-borne Zika, dengue, yellow fever, and West Nile viruses.2 JE virus is the leading cause of vaccine-preventable encephalitis in Asia and the western Pacific.1

The JE virus life cycle involves mosquitoes and vertebrate hosts, including wading birds and pigs. When bitten by an infected mosquito, humans can be infected. As the JE virus generally cannot multiply and persist in humans for the purpose of transmission, humans are dead-end hosts of the virus. Therefore, vaccination protects the individual but does not reduce the risk of infection in the population as a whole (herd immunity). Person-to-person transmission does not occur. 4,*

*Cases of JE transmission through the blood supply during transfusion of blood and platelets have been reported.5

What are the dangers of JE?

%

Mortality Rate

%

Long-Term Serious Complications

Specific Treatment

%

Mortality Rate

Up to 30% of those who develop symptomatic JE will die.1,4

%

Long-Term Serious Complications

Up to 50% of survivors continue to have neurologic, cognitive, and psychiatric impairments.1,4

Specific Treatment

There is no specific treatment for JE, but it can be prevented.1,3,4

Up to 30% of those who develop symptomatic JE will die.1,4

Up to 50% of survivors continue to have neurologic, cognitive, and psychiatric impairments.1,4

There is no specific treatment for JE, but it can be prevented.1,3,4

Complications of JE can include1,3,4 :

  • Cognitive and behavioral disturbances
  • Memory impairment
  • Cranial nerve defects
  • Sensory disturbances, including pain

  • Seizures

  • Neuromuscular dysfunction

  • Neurochemical and hormonal disturbances
  • Impairment of activities of daily living (ADLs)

JE can cause a heavy burden for survivors who must live with disability, as well as for their families, friends, and colleagues.

Mosquitoes may bite as soon as travelers arrive

JE cases by duration of travel for 37 reported travelers from 1973-20086

Long-Term
Travelers

Expatriates
Students studying in Asia
Soldiers

Short-Term
Travelers

Tourists

JE vaccination campaigns in Asia

In many countries where JE is a public health priority, JE vaccination is part of a national immunization schedule.7  Unfortunately, because the virus lifecycle is human-independent, immunization of the local population does not reduce the risk of JE to travelers.4

Mosquitoes may bite as soon as travelers arrive

JE cases by duration of travel for 37 reported travelers from 1973-200812

Long-Term
Travelers

Expatriates
Students studying in Asia
Soldiers

Short-Term
Travelers

Tourists

JE vaccination campaigns in Asia

In many countries where JE is a public health priority, JE vaccination is part of national immunization schedule.13  Unfortunately, because the virus lifecycle is human-independent, immunization of the local population does not reduce the risk of JE to travelers.4

Indication & Usage

IXIARO is a vaccine indicated for the prevention of disease caused by Japanese encephalitis virus, approved for use in individuals 2 months of age and older.

Important Safety Information

Severe allergic reaction after a previous dose of IXIARO, any other Japanese encephalitis vaccine,  or any component of IXIARO,  including protamine sulfate a compound known to cause hypersensitivity reactions in some individuals is a contraindication to administration of IXIARO.  Individuals with a history of severe allergic reaction to another Japanese encephalitis vaccine may be referred to an allergist for evaluation if immunization with IXIARO is considered.

Vaccination with IXIARO may not protect all individuals.  Individuals with a weakened immune system may have a diminished immune response to IXIARO.  Fainting may occur when receiving any injection, including IXIARO.  Tell your healthcare practitioner if you have a history of fainting from injections.

The most common (>10%) adverse reactions were: fever, irritability, diarrhea, and injection site redness in infants 2 months to <1 year of age; fever in children 1 to <12 years of age; pain and tenderness in adolescents 12 to <18 years of age; and, headache, muscle pain, and injection site pain and tenderness in adults.

You are encouraged to report negative side effects of vaccines to the US Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC). Visit www.vaers.hhs.gov or call 1-800-822-7967.  You should ask your healthcare practitioner for medical advice about adverse events.

For more information, please see the physician’s Prescribing Information and ask your healthcare practitioner about the risk and benefits of IXIARO.

 

 

 

Site is intended for travelers from the United States

1807-US-IX-044-1018 | 10/18 | Copyright © 2018 Valneva USA, Inc. All Rights Reserved.